→ Rubius Therapeutics $RUBY has posted some positive — though preclinical — study results on its red blood cell tech, saying they were able to track a desired immune response using their drugs.The therapies are designed to increase the flow of T cells to a tumor, mobbing cancer cells in the process.
→ Little Eidos $EIDX, which is going up against the giant Pfizer $PFE in developing a treatment designed to treat transthyretin amyloid cardiomyopathy (ATTR-CM), has run into accounting trouble in connection with its former auditor PwC. In a filing posted on Monday, the San Francisco-based drug developer said after a discussion with its new auditor Ernst & Young it will have to restate financial information for the first three quarterly periods in the year ended December 31, 2018.
→ Xencor has secured another partner in Japan’s Astellas just a few weeks after signing a $120 million co-development deal with Genentech. The biotech will devote its bispecific expertise to generating some oncology drug candidates, which Astellas can then license.
→ Ramsey, NJ-based ADMA Biologics is setting up commercialization for an intravenous immunoglobulin dubbed Asceniv in the second half of the year after the FDA approved it for primary humoral immunodeficiency disease. “Going forward, we believe this FDA approval better positions ADMA to further its mission to evaluate Asceniv in immune-compromised patients infected with or at-risk for Respiratory Syncytial Virus (“RSV”) infection,” said president and CEO Adam Grossman.
→ With its first-of-its-kind gene therapy for spinal muscular atrophy tipped for a blockbuster launch in 2019, Novartis’ AveXis has purchased a fourth manufacturing campus. The Longmont, Colorado facility — which formerly belonged to AstraZeneca — will be larger than the current or planned plants AveXis has in Illinois, North Carolina and San Diego. The company plans to retain around 150 employees who were recently let go, with plans to hire more soon.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,300+ biopharma pros who read Endpoints News by email every day.Free Subscription